Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD40HVac + poly-ICLC
- Development stage
- Unknown
- Lead developer
- Linkinvax
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
CD40HVac is a therapeutic vaccine designed for the treatment of HPV16-associated malignancies, specifically oropharyngeal squamous cell carcinoma. It consists of a humanized IgG4 monoclonal antibody targeting the CD40 receptor on dendritic cells, which is fused to the HPV16 E6 and E7 oncoproteins. This design allows for the direct delivery of viral antigens to dendritic cells, promoting a robust T-cell-mediated immune response. The vaccine is administered in combination with **poly-ICLC** (Hiltonol), a synthetic double-stranded RNA that acts as an immune adjuvant by stimulating Toll-like receptor 3 (TLR3) and MDA5 pathways. Developed by LinKinVax (formerly EnnoDC) in collaboration with Gustave Roussy, the combination is currently being evaluated in Phase I/IIa clinical trials for patients in remission following curative treatment for HPV16-positive oropharyngeal cancer.
- Other names
- HPV.DCVaxanti-HPV DC targeting vaccineCD40HVac-poly-ICLCCD-40HVac-poly-ICLCCD 40HVac-poly-ICLC
02
Targets
CD40 (Cluster of differentiation 40 receptor)IFIH1 (MDA5)TLR3 (Toll-like receptor 3)HPV16 E6 oncoproteinHPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on CD40HVac + poly-ICLC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD40HVac + poly-ICLC.